AstraZeneca pays Sobi $95M for priority review voucher

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 22, 2019 at 12:22 PM.

  1. #1 cafead, Aug 22, 2019 at 12:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via AstraZeneca has struck a $95 million deal to buy a FDA priority review voucher from Swedish Orphan Biovitrum. The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.

    article source
     
    Quote

Reply to Thread